The results of a clinical trial for lecanemab, an experimental drug that is claimed to slow the destruction of the brain in Alzheimer’s disease, were originally hailed by the mainstream/legacy media as a ‘momentous breakthrough.’ This was despite the fact that the drug’s effect is very small, it can only be used in the early stages of the disease, and its likely impact on patients’ daily lives is highly questionable.
The study results were published in the New England Journal of Medicine. The trial involved a total of 1,795 patients with early-stage Alzheimer’s, 898 of whom received the drug with the rest being given a placebo. Prior to the study, the participants were estimated to have an average clinical dementia rating of around 3.2, as measured on an 18-point evaluation scale, with higher numbers indicating greater cognitive impairment.
After 18 months, the clinical dementia rating for patients treated with lecanemab had worsened by 1.21 points, with the rating for the placebo group worsening by 1.66 points. In other words, the deterioration experienced by Alzheimer’s patients receiving the drug was only fractionally less than that of those who received no treatment at all. As we commented at the time, the mainstream/legacy media’s hyping of this drug was a clear case of putting marketing before science.
To read how scientists working at the Dr. Rath Research Institute have recently been exploring the effects of various natural substances against Alzheimer’s disease, see this article on our website.
COVID Shots 200 Times More Likely Than All Other Vaccines to Cause Blood Clots in Brain
August 2, 2024Dr. Rath’s Cellular Health Recommendations for Diabetes
August 2, 2024European Regulator Rejects Alzheimer’s Drug Lecanemab
News
The European Medicines Agency (EMA) has rejected a licence for an Alzheimer’s drug. The EMA said the benefits of lecanemab did not counterbalance the risk of serious side effects, especially bleeding and swelling in the brain.
[Source: bbc.co.uk]
[Image source: Adobe Stock]
Comment
The results of a clinical trial for lecanemab, an experimental drug that is claimed to slow the destruction of the brain in Alzheimer’s disease, were originally hailed by the mainstream/legacy media as a ‘momentous breakthrough.’ This was despite the fact that the drug’s effect is very small, it can only be used in the early stages of the disease, and its likely impact on patients’ daily lives is highly questionable.
The study results were published in the New England Journal of Medicine. The trial involved a total of 1,795 patients with early-stage Alzheimer’s, 898 of whom received the drug with the rest being given a placebo. Prior to the study, the participants were estimated to have an average clinical dementia rating of around 3.2, as measured on an 18-point evaluation scale, with higher numbers indicating greater cognitive impairment.
After 18 months, the clinical dementia rating for patients treated with lecanemab had worsened by 1.21 points, with the rating for the placebo group worsening by 1.66 points. In other words, the deterioration experienced by Alzheimer’s patients receiving the drug was only fractionally less than that of those who received no treatment at all. As we commented at the time, the mainstream/legacy media’s hyping of this drug was a clear case of putting marketing before science.
To read how scientists working at the Dr. Rath Research Institute have recently been exploring the effects of various natural substances against Alzheimer’s disease, see this article on our website.
Dr. Rath Health Foundation
Related posts
Vitamin C Can Boost Placental Health in Smokers
Read more